Gene-Edited cell therapy for lupus trial pulled before it started
NCT ID NCT06752876
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-stage study aimed to test a single infusion of CB-010, a CRISPR-edited CAR-T cell therapy made from donor cells, in people with severe lupus that did not respond to standard treatments. The trial was withdrawn before enrolling any participants, so no results are available. The approach was designed to target and destroy faulty immune cells that drive lupus, but its safety and effectiveness remain untested.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CB-010 (a CRISPR-edited CAR-T cell therapy made from donor cells)
What this could lead to
If it works, this could point toward a new treatment option for people with severe lupus that hasn't responded to other therapies.
What could go wrong
This trial was withdrawn before enrolling any participants, so no data is available. CAR-T therapies carry risks like cytokine release syndrome and infections, and long-term safety is unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.